GO
| HSI1 | 25,063.71 | +681.24 | 303.07B |
| HSCEI1 | 8,499.53 | +191.71 | 100.62B |
| Back Zoom + Zoom - Block Traded | |
|
2026-03-24 17:45:46 WUXI BIO (02269.HK) announced its full-year results for the year ended December 31, 2025. Revenue reached RMB21.79 billion, a YoY rise of 16.7%. It recorded net profit of RMB4.908 billion, a YoY hike of 46.3%, with an EPS of RMB1.22. Gross profit added by 30.9% YoY to RMB10.019 billion, and the gross profit margin improved by 5% YoY to 46%. Excluding share-based compensation expense, foreign exchange gains or losses, gains or losses from equity investments, assets divestiture and retirement, and related one-time costs, the Group's adjusted net profit grew 17.9% to RMB5.64 billion, and the adjusted net profit margin lifted by 0.3 ppts to 25.9%. No dividend was declared. ~ AAStocks Financial News Web Site: www.aastocks.com | |